Drug Profile
ATL 1102
Alternative Names: ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102Latest Information Update: 24 Apr 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Antisense Therapeutics; Childrens Hospital Los Angeles
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antisense oligonucleotides
- Mechanism of Action Integrin alpha4 inhibitors; Integrin alpha4beta1 antagonists; RNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma; Multiple sclerosis
Highest Development Phases
- Phase II Duchenne muscular dystrophy; Multiple sclerosis
- Preclinical Limb girdle muscular dystrophies
- No development reported Asthma; Cancer
- Discontinued Stem cell mobilisation; Vertigo
Most Recent Events
- 24 Apr 2023 Phase-II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in Bulgaria (SC) as of April 2023 (EudraCT2022-003065-38)
- 22 Jun 2022 Preclinical trials in Limb girdle muscular dystrophies in Australia (unspecified route)
- 22 Jun 2022 Early pharmacodynamics data from a preclinical trial in Limb girdle muscular dystrophies released by Aantisense Therapeutics